BiologicalDrug
Relmacabtagene autoleucel clinical trials
Also written JWCAR029 and Relma-cel.
Keep track of what changes. Save the relmacabtagene autoleucel studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Other names
Combined with it in one product
Studies by the year they started
14 studies that test it; most in 2023 (5)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 9
Shanghai Ming Ju Biotechnology Co., Ltd. (5) · Ruijin Hospital (2) · Zhengzhou University (1) · Changhai Hospital (1) · Sun Yat-sen University (1) · Liangjing Lu (1) · Peking University Cancer Hospital & Institute (1) · Peking University (1)
Often tested with
Tested in the same studies.
Transplantation (1) · Sintilimab (1)
Studies
Open first, then newest update. How each study uses relmacabtagene autoleucel is read from its arms, and is right about nine times in ten.
Testing it · 14
- Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell LymphomaRecruitingPhase 2Sun Yat-sen UniversityNCT07077512Written as Autoleucel (Relmacabtagene Autoleucel)
- CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic FactorsRecruitingPhase 2Ruijin HospitalNCT06365671Written as Relmacabtagene autoleucel (relma-cel)
- Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System LymphomaNot yet recruitingNot applicableZhengzhou UniversityNCT07198464Written as Relmacabtagene autoleucel and transplantation
- Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell LymphomaRecruitingPhase 4Ruijin HospitalNCT05806580Written as Relma-cel
- CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell LymphomaRecruitingPhase 2Shanghai Ming Ju Biotechnology Co., Ltd.NCT06479356Written as Relma-cel
- Relmacabtagene Autoleucel for the Treatment of Systemic SclerosisRecruitingPhase 1Liangjing LuNCT06414135Written as Relma-cel
- Relma-cel for Moderate to Severe Active Systemic Lupus ErythematosusNot yet recruitingPhase 1Shanghai Ming Ju Biotechnology Co., Ltd.NCT06297408Written as Relma-cel
- Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell LymphomaRecruitingPhase 2Peking University Cancer Hospital & InstituteNCT05590221Written as Relmacabtagene Autoleucel
- A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell LymphomaNot yet recruitingPhase 4Changhai HospitalNCT05814848Written as Relmacabtagene Autoleucel Injection
- CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus ErythematosusRecruitingPhase 1Shanghai Ming Ju Biotechnology Co., Ltd.NCT05765006Written as Relma-cel
- Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHLActive, not recruitingPhase 2Shanghai Ming Ju Biotechnology Co., Ltd.NCT06093841Written as Relmacabtagene Autoleucel
- CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell LymphomaCompletedPhase 1Shanghai Ming Ju Biotechnology Co., Ltd.NCT04812691Written as JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)
- Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaStatus unknownPhase 1Peking UniversityNCT03344367Written as JWCAR029
- Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaStatus unknownPhase 1Zhao WeiliNCT03355859Written as JWCAR029
Given in every arm · 1 — relmacabtagene autoleucel is usual care beside what is tested
Codes
What other systems call relmacabtagene autoleucel · ClinicalTrials.gg INT001675
- MeSH (NLM) C000718412relmacabtagene autoleucelConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) K5CXA4X5U8RELMACABTAGENE AUTOLEUCELConfirmed FDA, NLM
- NCI Thesaurus C155878Relmacabtagene AutoleucelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718412 | relmacabtagene autoleucel | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | K5CXA4X5U8 | RELMACABTAGENE AUTOLEUCEL | Confirmed FDA, NLM |
| NCI Thesaurus | C155878 | Relmacabtagene Autoleucel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.